- Home
- DAVE vs CVAC Comparison
DAVE vs CVAC Comparison
Compare DAVE & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVE | CVAC |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 1.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DAVE | CVAC |
|---|---|---|
| Price | $237.48 | $4.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $282.17 | $6.83 |
| AVG Volume (30 Days) | 351.2K | ★ 1.3M |
| Earning Date | 11-04-2025 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 224.46 | 94.02 |
| EPS | ★ 10.12 | 0.94 |
| Revenue | ★ $491,301,000.00 | $83,000,117.00 |
| Revenue This Year | $56.88 | N/A |
| Revenue Next Year | $18.07 | $23.71 |
| P/E Ratio | $23.05 | ★ $4.98 |
| Revenue Growth | ★ 53.84 | N/A |
| 52 Week Low | $65.46 | $2.48 |
| 52 Week High | $286.45 | $5.72 |
Technical Indicators
Market Signals| Indicator | DAVE | CVAC |
|---|---|---|
| Relative Strength Index (RSI) | 62.53 | 47.92 |
| Support Level | $208.15 | $4.26 |
| Resistance Level | $236.00 | $4.68 |
| Average True Range (ATR) | 11.73 | 0.17 |
| MACD | 2.33 | 0.04 |
| Stochastic Oscillator | 81.65 | 62.56 |
Price Performance
Historical ComparisonAbout DAVE Dave Inc.
Dave Inc is a financial services company. It is engaged in offering banking app that offers its customers banking, financial insights, overdraft protection, building credit and finding side gigs.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.